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Abstract—Evenomation by arachnids of the genus Loxosceles frequently results in
disfiguring necrotic skin lesions. The cellular and molecular mechanisms which
contribute to lesion development are incompletely defined but appear to involve
participation of several pro-inflammatory mediators. We have recently observed that
Loxosceles deserta venom induces the production of chemokines in human umbilical
vein endothelial cells (HUVECs) and human pulmonary epithelial cells. In the
present study we observed that Loxosceles deserta venom induces the expression of
vascular endothelial growth factor (VEGF) in human keratinocytes but little in smooth
muscle cells and none in pulmonary epithelial cells. A potent endothelial cell-specific
mitogen, VEGF induces angiogenesis and vascular permeability in vivo. RNase
protection assay data indicate that VEGF mRNA concentrations in keratinocytes are
significantly increased at 2 h following venom exposure. These data suggest that
keratinocyte-derived VEGF may contribute to the vasodilation, edema and erythema
which occur following Loxosceles evenomation.
INTRODUCTION
The most important North American arachnid that causes tissue necrosis is Lox-
osceles reclusa, commonly known as the brown recluse spider (1). The clinical
spectrum of brown recluse spider-induced wounds can range from a small lesion
marked by local pain and erythema to a much more serious would marked by
extensive, often refractory dermal necrosis. Occasionally, individuals bitten by
Loxosceles spiders exhibit systemic manifestations including nausea, vomiting,
fever, chills, arthralgia, hemolysis, renal failure, and even death (2).
Although experimental dermonecrotic lesions with Loxosceles venom are
readily produced in guinea pigs and rabbits, the mechanism of venom action
remains incompletely defined. Animal studies and in vitro analyses of venom-
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induced cell activation suggest that a variety of soluble proinflammatory medi-
ators participate in lesion development. We recently observed that Loxosceles
deserta venom is a potent inducer of chemokine production by both endothelial
and epithelial cells (3). Furthermore, Loxosceles deserta venom-induced chemo-
kine expression in HUVECs is mediated by members of the Rel/ NF-kB family
of transcription factors (4). VEGF (vascular endothelial growth factor), also des-
ignated VPF (vascular permeability factor) is a potent endothelial cell-specific
mitogen which induces angiogenesis and vascular permeability in vivo. VEGF
is expressed in normal epidermis. Overexpression of VEGF by epidermal cells
has been reported in certain non-neoplastic processes characterized by increased
microvascular permeability and angiogenesis, e.g. wound healing, psoriasis and
diseases associated with blister formation (5). Accordingly, VEGF is believed
to be a major skin-derived cytokine that regulates local dermal microvascular
permeability and angiogenesis. In the studies presented herein we observed that
Loxosceles venom specifically induces the production of VEGF in human ker-
atinocytes but not in smooth muscle cells (SMCs) or pulmonary epithelial cells.
These results suggest that Loxosceles deserta may be a potent inducer of VEGF
expression in human skin which in turn may contribute to lesion formation.
METHODS
Loxosceles deserta venom was purchased from Spider Pharm, Feasterville, Pennsylvania.
Recombinant human TNF-a and IL-1b were obtained from R&D Systems Minneapolis, Minnesota).
Endothelial Cell Culture. Human umbilical vein endothelial cells were isolated from umbilical
cords by treatment with 0.1% collagenase in Dulbecco’s phosphate buffered saline (Bio Whittaker,
Walkersville, Maryland) as previously described (6). Cells were grown and maintained in M199
medium (Bio Whittaker) supplemented with 20% heat-inactivated fetal bovine serum, L-glutamine
(1.3 mM), penicillin (100 units/ ml), streptomycin (100 mg/ ml), fungizone (0.25 mg/ ml), endothelial
cell growth supplement (25 mg/ ml) and bovine lung heparin (100 mg/ ml). Cells were plated onto
gelatin-coated 150 × 25 mm plates, allowed to grow to confluence at 378C in 5% CO2, and utilized
between the first and third passage.
Human Aorta Vascular Smooth Muscle Cell Culture. Human aorta vascular smooth muscle
cells were purchased from Clonetics (Walkersville, Maryland) and were grown and maintained in
smooth muscle cell basal medium (SmBm) supplemented with human recombinant epidermal growth
factor (hEGF, 10 mg/ ml), human recombinant fibroblast growth factor (hFGF, 1 mg/ ml), dexametha-
sone (0.39 mg/ ml), gentamicin (50 mg/ ml), amphotericin-B (50 mg/ ml) and FBS (5%). The cells
were used between the fifth and eighth passage.
Keratinocyte Culture. Pooled normal human epidermal keratinocytes from neonatal skin were
obtained from Clonetics. They were grown and maintained in keratinocyte basal medium (KBM)
which was supplemented with rhEGF (0.1 mg/ ml), insulin (5.0 mg/ ml), hydrocortisone (0.5 mg/ ml),
gentamicin (50 mg/ ml), amphotericin-B (50 mg/ ml) and bovine pituitary extract (0.4%). The ker-
atinocytes were used between their first and fifth passage.
Pulmonary Epithelial (A549) Cell Culture. Human pulmonary epithelial A549 cells were pur-
chased from ATCC (Manassas, Virginia) and were grown and maintained in M199 medium (Bio
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Whittaker) supplemented with PSF (penicillin (100 units/ ml), streptomycin (100 mg/ ml), fungizone
(0.25 mg/ ml), 1 mM glutamine, 25 mM HEPES and 15% fetal bovine serum.
Whole Cell (WC) Enzyme Immunoassay for VEGF. Cells were cultured on 96-well flat bottom
polystyrene plates (Costar) and were used for experiments after reaching confluence. VEGF capture
plates were prepared by coating sterile 96-well flat bottom ELISA plates (Corning, Corning, New
York) with anti-human VEGF antibody (R&D Systems, 100 ml/ well, 0.8 mg/ ml in PBS). The plates
were incubated at 48C overnight, washed 5 times with Wash Buffer (0.05% Tween-20 in PBS, pH
7.4) and blocked overnight at 48C with blocking buffer (0.05% Tween-20, 1% BSA in PBS, pH
7.4) to reduce nonspecific binding. Capture plates were again washed 5 times with wash buffer
and stored at 48C until use. Following an 8 h exposure of cells to cytokines or Loxosceles venom,
conditioned cell media were collected. 100 ml aliquots of the conditioned cell media and human
recombinant VEGF standards (R&D systems) were loaded onto capture plates and incubated at 48C
overnight. Plates were washed 5 times with wash buffer. Biotinylated anti-human VEGF detection
antibody (R&D Systems) was added to each well (0.1 mg/ ml, 100 ml per well) and plates were
incubated at room temperature for 2 h. After 3 washes, streptavidin horseradish peroxidase was
added (Neutralite avidin, Southern Biotechnology Associates, Birmingham, Alabama; 100 ml/ well,
1 : 4000 dilution) and incubated for 30 min at room temperature. Wells were washed 4 times to
remove unbound conjugated peroxidase and then incubated with 100 ml/ well of peroxidase substrate
(ABTS, Boehringer Mannheim Biochemica, Germany). After 0.5–4 h absorbance at 405 nm was
measured using an automated microplate reader (ELX808, Bio-Tek Instruments, Winooski, Vermont).
VEGF concentrations were calculated by 4 parameter curve fitting or linear regression analysis of
rhVEGF standard curves using KC3 software (Bio-Tek Inc.).
RNase Protection Assay. Total RNA was extracted from keratinocytes using Tri Reagent
(Sigma) according to manufacturer’s instructions. The RNase protection assays were performed using
the RiboQuant Multi-probe kit from Pharmingen (San Diego, California) and carried out according to
manufacturer’s directions. Briefly, angiogenesis probes were radiolabeled with [g c32P] UTP (Amer-
sham) and hybridized with the extracted total RNA at 568C overnight. RNase digestion was carried
out at 308C for 45 min to degrade unhybridized single-stranded and excess probe and terminated
by the addition of Proteinase K. After phenol/ chloroform extraction and ammonium acetate/ ethanol
precipitation, the hybridized RNA probes were denatured at 908C for 3 min and loaded onto a 4.75%
denaturing polyacrylamide gel which was run in 0.5 X TBE at 50 watts constant power overnight.
Gels were vacuum dried at 508C for 90 min, placed on Kodak X-OMAT film in an autoradiography
cassette with an intensifying screen and developed at −708C.
Statistical Analysis. All values are expressed as the means ± standard error. Data were ana-
lyzed using Friedman two way analysis of variance (ANOVA) with Bonferroni comparison of means.
Probability (P) values of <0.05 were considered significant.
RESULTS
IL-1b but not TNF-a or Loxosceles deserta Venom Induces VEGF Expres-
sion in A549 Cells. In the presence of medium alone, A549 cells produced a
small quantity of VEGF over an 8 h period (Figure 1). Exposure to 0.2, 2.0
and 20.0 ng/ ml of interleukin-1b (IL-1b), respectively, resulted in significant
increases in VEGF secreted into the medium while cells that had been exposed
to tumor necrosis factor-a (TNF-a, 0.2–2.0 ng/ ml) did not produce significantly
higher concentrations of VEGF than cells exposed to medium alone. A549 epi-
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Fig. 1. VEGF secretion by A549 human pulmonary epithelial cells in response to IL-1b (lanes
a-d), TNF-a (lanes e-h), and Loxosceles deserta venom (lanes i-n). ANOVA P c 0.0016 vs. controls.
Asterisk* indicates significant difference from controls as determined by Bonferroni comparison of
means.
thelial cells incubated in the presence of Loxosceles deserta venom (0.195–50
mg/ ml) did not secrete significantly higher concentrations of VEGF than con-
trols.
Loxosceles deserta Venom Induces Low Levels of VEGF Expression in
Human Aorta Vascular Smooth Muscle Cells. Smooth muscle cells produce
VEGF in response to a variety of cytokines and growth factors (7). Exposure
of human aorta vascular smooth muscle cells to IL-1b resulted in marked dose-
dependent VEGF secretion whereas TNF-a produced only moderate increases
(Figure 2). Exposure of SMCs to Loxosceles deserta venom in doses ranging
from 0.391 to 25 mg/ ml resulted in modest increases in VEGF secretion at only
2 concentrations of venom (0.781 and 25 mg/ ml). However, even at these con-
centrations, the quantity of VEGF secreted by venom-activated smooth muscle
cells was much lower than the quantity induced by IL-1b.
Loxosceles deserta Venom is a Potent Stimulus for VEGF Secretion in
Human Keratinocytes. Exposure of keratinocytes to the cytokines IL-1b or
TNF-a at doses ranging from 0.2 to 20 ng/ ml, respectively, failed to induce sig-
nificant increases in VEGF concentrations (Figure 3). Incubation of keratinocytes
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Fig. 2. Effects of IL-1b (lanes a-d), TNF-a (lanes e-h), and Loxosceles deserta venom (lanes i-p) on
VEGF expression in human aorta vascular smooth muscle cells. ANOVA P c 0.0004 vs. controls.
Asterisk* indicates significant difference from controls as determined by Bonferroni comparison of
means.
with Loxosceles deserta venom at concentrations ranging from 0.195 to 50
mg/ ml, resulted in marked, dose-dependent increases in VEGF concentrations.
At a dose of 3.125 mg/ ml, VEGF concentrations were increased by more than
200% above control values.
Exposure to Loxosceles deserta Venom Results in Increased Concentra-
tions of VEGF mRNA in Keratinocytes. In order to determine whether increased
synthesis of VEGF mRNA was induced in venom-activated keratinocytes, we
utilized a multi-probe RNase protection assay. The assay included probes for
VEGF-C, an angiogenic factor that is structurally and functionally related to
VEGF (8). Figure 4 depicts the time course for the appearance of VEGF mRNA
in keratinocytes incubated in presence of 3.125 mg/ ml Loxosceles venom. Low
concentrations of VEGF mRNA are present in unstimulated keratinocytes (lane
1). At 2 h following exposure to Loxosceles deserta venom (lane 2) VEGF
transcripts were present in concentrations significantly increased over concen-
trations of VEGF mRNA observed in keratinocytes exposed to medium alone
(lane 1). At 4 h, VEGF mRNA concentrations returned to background (lane 3)
and remained at background levels even at 6 h following exposure to Loxosce-
les venom (lane 4). Consistent with the results from ELISA experiments (Figure
3), VEGF transcripts were not significantly increased in response to TNF-a (Fig-
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Fig. 3. VEGF secretion by human keratinocytes in response to increasing concentrations of IL-1b
(lanes a-d), TNF-a (lanes e-h), and Loxosceles deserta venom (lanes i-n). ANOVA P c 0.0041
vs. controls. Asterisk* indicates significant difference from controls as determined by Bonferroni
comparison of means.
Fig. 4. Induction of VEGF mRNA in Loxosceles deserta-activated keratinocytes. RNase protection
assays were utilized in order to detect specific transcripts for VEGF, VEGF-C and for the “house-
keeping” genes L32 and GAPDH as controls. Keratinocytes were exposed to 1. Medium only (lane
1) 2. Venom for 2, 4, and 6 h, respectively (lanes 2–4) or 3. TNF-a (lane 5).
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ure 4, lane 5). No significant changes in the concentrations of VEGF-C mRNAs
were observed, suggesting that the increase in VEGF mRNA concentrations in
keratinocytes is a specific response to venom exposure.
DISCUSSION
We previously observed that endothelial and pulmonary A549 epithe-
lial cells exposed to Loxosceles deserta venom secrete a variety of chemo-
kines including monocyte chemoattractant protein-1 (MCP-1), growth-related
oncogene-alpha (GRO a) and interleukin-8 (IL-8) (3). Patel et al. reported that
exposure of HUVECs to Loxosceles venom results in the induction of E-selectin
and granulocyte-macrophage-colony-stimulating factor (GM-CSF) (9).
In vivo studies indicate that within 6 h following Loxosceles evenomation,
both epidermal and dermal edema are observed. Histopathologic findings include
the marked infiltration of venular walls by neutrophils, vasodilation, intravascu-
lar thrombosis, and massive hemorrhage into the adjacent dermis, subcutis, and
sometimes into adjacent muscle. Bite sites are further characterized by fibri-
noid necrosis and vacuolization of arteriole wall cells with resultant disruption
of arteriolar integrity (10). VEGF, also known as VPF, is a potent endothelial cell
mitogen which induces angiogenesis in vivo (11). On a molecular basis VEGF is
approximately 50,000-fold more potent in inducing vascular permeability than
histamine (12). The structural basis of the induction of vascular permeability
by VEGF is not well understood but it has been speculated that upon binding
of VEGF to its receptors, cytoskeletal changes occur which result in cell con-
traction and increased intercellular vascular permeability (11). VEGF has also
been shown to induce fenestrations in endothelial cells in vivo and thus convert
endothelium from a non-fenestrated into a fenestrated phenotype (11).
Some of the activities of VEGF can be considered to be pro-inflammatory
(13). For example, enhanced vascular permeability is one of the earliest events
in the inflammatory response. Moreover, VEGF is a chemoattractant for mono-
cytes. Finally, VEGF has been shown to enhance the activity of TNF-a in the
regulation of the expression of at least 2 endothelial cell proteins, tissue fac-
tor and Glut-1 glucose transporter (13). Several reports indicate that VEGF is
expressed in human dermis where it may act as a regulator of vascular homeo-
stasis (5). Increased expression of VEGF has been observed in the epidermis of
healing skin wounds (12), in psoriatic skin lesions (14) and in bullous diseases
associated with subepidermal blister formation (15).
Keratinocytes constitute approximately 95% of the cell mass of human epi-
dermis and have increasingly come to be recognized as important regulators of
inflammation (12, 16). Keratinocytes contain and express cytokines that promote
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chemotaxis, activate macrophages and bone marrow elements, and induce lym-
phocyte homing (12). Recently Detmar et al. reported that transforming growth
factor-a (TGF-a) and epidermal growth factor (EGF), two factors that have been
associated with the pathogenesis of wound healing and/ or psoriasis, as well as
phorbol myristate acetate (PMA), markedly stimulate VEGF mRNA expression
and VEGF secretion in cultured keratinocytes (17). The VEGF secreted by ker-
atinocytes was biologically active in that it is a potent stimulus of dermal endo-
thelial cell proliferation.
Studies with genetically diabetic db/ db mice that are characterized by a
severe delay in skin repair have identified VEGF as an important cytokine par-
ticipating in wound healing (18). During the healing process, continued vascu-
lar permeability results in extravasation of fibrinogen that serves as a provisional
matrix and promotes angiogenesis and scar formation (12). However, the wound
healing defect in db/ db mice is associated with reduced levels of VEGF during
skin repair suggesting that up-regulation of VEGF is essential for normal wound
healing (18).
In the present study we observed that human keratinocytes but not human
aorta smooth muscle cells or epithelial cells secrete high concentrations of VEGF
in response to Loxosceles deserta venom. The concentration of VEGF pro-
duced in presence of venom greatly exceeds that produced by either TNF-a or
IL-1b (0.2–20 ng/ ml) stimulation of keratinocytes. In addition, exposure of ker-
atinocytes to Loxosceles venom results in a significant increase in VEGF mRNA
concentrations at 2 h following exposure to venom. These data suggest that fol-
lowing Loxosceles evenomation, VEGF expression may be rapidly upregulated
in the dermis where it may act in concert with other pro-inflammatory mediators
such as MCP-1, IL-8, E-selectin and GM-CSF. At least in part, VEGF may be
responsible for the edema and erythema seen early after evenomation. Although
not addressed in the present study, these observations may also suggest a role
for VEGF in the wound healing process following Loxosceles evenomation.
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